3-O-Acetyl-11-keto-boswellic Acid Decreases Basal Intracellular Ca2+ Levels and Inhibits Agonist-Induced Ca2+ Mobilization and Mitogen-Activated Protein Kinase Activation in Human Monocytic Cells
- Institute of Pharmaceutical Chemistry, University of Frankfurt, Frankfurt, Germany (D.P., L.T., S.G.); Institute of Organic Chemistry, University of Saarland, Saarbrücken, Germany (J.J.); and Department of Pharmaceutical Analysis, Institute of Pharmacy, Eberhard-Karls-University Tubingen, Tubingen, Germany (O.W.)
- Address correspondence to:
Dr. Oliver Werz, Department of Pharmaceutical Analysis, Institute of Pharmacy, Eberhard-Karls-University Tubingen, Auf der Morgenstelle 8, 72076 Tubingen, Germany. E-mail: o.werz{at}pharmchem.uni-frankfurt.de
Abstract
Previously, we showed that 11-keto-boswellic acid and 3-O-acetyl-11-keto-BA (AKBA) stimulate Ca2+ mobilization and activate mitogen-activated protein kinases (MAPKs) in human polymorphonuclear leukocytes (PMNLs). Here, we addressed the effects of boswellic acids on the intracellular Ca2+ concentration ([Ca2+]i) and on the activation of p38MAPK and extracellular signal-regulated kinase (ERK) in the human monocytic cell line Mono Mac (MM) 6. In contrast to PMNLs, AKBA concentration dependently (1–30 μM) decreased the basal [Ca2+]i in resting MM6 cells but also in cells where [Ca2+]i had been elevated by stimulation with platelet-activating factor (PAF). AKBA also strongly suppressed the subsequent elevation of [Ca2+]i induced by N-formyl-methionyl-leucyl-phenylalanine (fMLP), PAF, or by the direct phospholipase C activator 2,4, 6-trimethyl-N-(meta-3-trifluoromethyl-phenyl)-benzenesulfonamide, but AKBA failed to prevent Ca2+ signals induced by thapsigargin or ionomycin. Suppression of Ca2+ homeostasis by AKBA was also observed in primary monocytes, isolated from human blood. Moreover, AKBA inhibited the activation of p38MAPK and ERKs in fMLP-stimulated MM6 cells. Although the effects of AKBA could be mimicked by the putative phospholipase C (PLC) inhibitor U-73122 (1-[6-[[17β-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione), AKBA appears to operate independent of PLC activity since the release of intracellular inositol-1,4,5-trisphosphate evoked by 2,4,6-trimethyl-N-(meta-3-trifluoromethyl-phenyl)-benzenesulfonamide was hardly diminished by AKBA. Inhibitor studies indicate that AKBA may decrease [Ca2+]i by blocking store-operated Ca2+ and/or nonselective cation channels. Together, AKBA interferes with pivotal signaling events in monocytic cells that are usually required for monocyte activation by proinflammatory stimuli. Interruption of these events may represent a possible mechanism underlying the reported anti-inflammatory properties of AKBA.
Footnotes
-
This work was supported by Deutsche Forschungsgemeinschaft Grants WE 2260/4-1 and GRK 757.
-
doi:10.1124/jpet.105.089466.
-
ABBREVIATIONS: BA, boswellic acid; 5-LO, 5-lipoxygenase; NF, nuclear factor; TNF, tumor necrosis factor; PAF, platelet-activating factor; fMLP, N-formyl-methionyl-leucyl-phenylalanine; MAPK, mitogen-activated protein kinase; PMNL, polymorphonuclear leukocyte; MM, Mono Mac; AKBA, 3-O-acetyl-11-keto-boswellic acid; ERK, extracellular signal-regulated kinase; m-3M3FBS, 2,4,6-trimethyl-N-(meta-3-trifluoromethyl-phenyl)-benzenesulfonamide; U-73122, 1-[6-[[17β-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione; 2-APB, 2-aminoethoxydiphenylborate; PBS, phosphate-buffered saline; PGC buffer, PBS containing 1 mg/ml glucose and 1 mM CaCl2; PG, PBS plus 1 mg/ml glucose; PAGE, polyacrylamide gel electrophoresis; DMSO, dimethyl sulfoxide; SDS-b, 2× SDS-PAGE sample loading buffer; IP3, inositol-1,4,5-trisphosphate; KBA, 11-keto-boswellic acid; AβBA, 3-O-acetyl-boswellic acid; PLC, phospholipase C; TG, thapsigargin; SOCC, store-operated Ca2+ channel; LOE908, (R,S)-(3,4-dihydro-6,7-dimethoxy-isoquinoline-1-yl)-2-phenyl-N,N-di-[2-(2,3,4-trimethoxyphenyl) ethyl]-acetamide; SK&F96365, 1-[β-[3-(4-methoxyphenyl)propoxy]-4-methoxyphenethyl]-1H-imidazole hydrochloride; NSCC, nonselective cation channel; SEA0400, 2-[4-[(2,5-difluorophenyl)methoxy]phenoxy-5-ethoxyaniline; KB-R7943, 2-[2-[4-(4-dinitrobenzyoxy)phenyl]ethyl]isothiourea.
-
- Received May 12, 2005.
- Accepted September 15, 2005.
- The American Society for Pharmacology and Experimental Therapeutics



